Could propranolol be beneficial in adult cerebral cavernous malformations?

19Citations
Citations of this article
41Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Surgery is the only therapeutic option for cerebral cavernous malformations (CCM) and is proposed, whenever possible, after haemorrhagic events, neurological symptoms, or epilepsy, radiosurgery being a controversial alternative in some cases. However, there is no treatment for non-accessible lesions, such as brainstem CCM, multiple CCM, or those located in functional areas. Propranolol, a non-selective beta-blocker used as first-line treatment for infantile haemangiomas, has proved spectacularly effective in a few cases of adult patients with CCM. We herein review the histological, in vitro data and clinical findings that support the idea of propranolol as a potential treatment for CCM. Since one retrospective study has not been conclusive, we support the idea that prospective trials are necessary.

Cite

CITATION STYLE

APA

Apra, C., Dumot, C., Bourdillon, P., & Pelissou-Guyotat, I. (2019, June 1). Could propranolol be beneficial in adult cerebral cavernous malformations? Neurosurgical Review. Springer Verlag. https://doi.org/10.1007/s10143-018-01074-0

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free